At the heart of this transformative study lies the application of cutting-edge single-cell RNA sequencing techniques, allowing an exhaustive dissection of perivascular adipose tissue at an unparalleled resolution. Unlike traditional bulk tissue analyses, which provide averaged gene expression profiles and obscure cellular heterogeneity, single-cell approaches elucidate the diverse cellular subtypes composing the stromal environment of the vasculature. By meticulously characterizing thousands of individual cells, the researchers generated a comprehensive “atlas” detailing the molecular signatures, lineage relationships, and functional potential of resident cells in perivascular fat.

The perivascular adipose tissue, a metabolically active fat depot intimately surrounding blood vessels, has long been recognized as a dynamic player in vascular homeostasis and inflammation. However, its cellular composition, especially the identity of stem and progenitor populations capable of influencing vascular remodeling, remained elusive until now. The identification of CD55—a complement regulatory protein—as a defining marker of a novel adipose-derived stem cell subset underscores the complexity and specificity of stromal components involved in vascular pathophysiology.

These CD55-positive adipose-derived stem cells exhibit a unique transcriptomic profile indicative of their capacity to respond adaptively to inflammatory and metabolic cues associated with atherosclerosis. Notably, the cells demonstrate an ability to influence extracellular matrix deposition, smooth muscle cell behavior, and endothelial integrity, thus actively shaping the remodeling processes that dictate plaque development and vessel wall stability. This finding challenges previous assumptions that adipose tissue merely plays a passive role in cardiovascular disease, highlighting instead a nuanced intercellular dialogue critical to disease progression.

Mechanistically, the study reveals that CD55+ stem cells modulate vascular remodeling through paracrine signaling and direct cell-cell interactions, orchestrating an environment conducive to either homeostasis or maladaptive remodeling depending on pathological context. Key signaling pathways implicated include those involved in inflammation, fibrogenesis, and angiogenesis, each pivotally contributing to the balance between repair and pathological thickening of the vascular wall. These insights underscore the dualistic nature of adipose-derived stem cells as both guardians and potential antagonists in vascular health.

Furthermore, by employing advanced lineage-tracing models and functional assays, the researchers demonstrated the pivotal role of CD55+ stem cells in in vivo models of atherosclerosis. Ablation or functional inhibition of this population significantly altered disease trajectory, attenuating plaque formation and improving vascular function. Conversely, expansion or activation of these cells exacerbated disease features, suggesting potential targets for pharmacological intervention designed to recalibrate their activity and promote vascular repair mechanisms.

Beyond the implications for atherosclerosis per se, this single-cell atlas provides a valuable resource for exploring how perivascular adipose tissue contributes more broadly to vascular biology and systemic metabolic regulation. As obesity and metabolic syndrome continue their global rise, understanding the cellular and molecular underpinnings linking adiposity, inflammation, and cardiovascular disease takes on increasing urgency. This study delivers critical insights into how discrete cell populations within fat tissue interface with blood vessels to modulate disease states.

Importantly, the identification of CD55 as a functional marker offers practical translational opportunities. Therapeutic strategies could be designed to selectively target CD55+ stem cells or their signaling pathways, aiming to harness their regenerative potential or mitigate their pathogenic contributions. Such approaches hold promise not only for the treatment of advanced atherosclerosis but also for preventative interventions in at-risk populations, potentially transforming clinical management paradigms.

The engineering of cell-specific therapeutics necessitates an in-depth understanding of the molecular identity and behavior of target cells under pathological conditions—insights now made accessible through this single-cell dataset. The detailed characterizations of gene expression patterns, surface markers, and intercellular communications provide a robust framework for developing precision medicine approaches. This aligns with the broader movement in cardiovascular medicine toward treatments tailored to patient-specific pathophysiology grounded in cellular biology.

Moreover, this research challenges the historical siloing of adipose tissue as merely an energy reservoir or inflammatory contributor by placing it at the confluence of vascular remodeling processes. The discovery situates perivascular adipose-derived stem cells as active participants in disease microenvironments, capable of both promoting repair and facilitating disease progression—an ambivalence with critical therapeutic implications. Understanding the regulatory switches that govern this duality could lead to more sophisticated, context-dependent interventions.

The technical prowess displayed in generating this atlas also heralds the maturation of single-cell technologies in cardiovascular research. Combining transcriptomics with spatial profiling, lineage tracing, and functional validation represents a comprehensive methodological approach that sets a new standard in the field. This integrative framework is anticipated to inspire parallel investigations targeting other adipose depots and vascular beds, broadening our understanding of adipose-vascular interplay.

Encapsulating these findings, the significance of the perivascular adipose tissue in health and disease has been profoundly redefined. This new atlas not only reshapes the landscape of atherosclerosis research but also invites a reevaluation of adipose tissue’s multifaceted roles in systemic physiology. Future studies building on this work will likely explore how environmental factors, aging, and comorbidities influence the behavior of CD55+ stem cells, further contextualizing their impact across diverse clinical scenarios.

In a clinical context, the findings propel the field toward diagnostic innovations as well. The presence and activity of CD55+ stem cells or their secreted mediators may serve as biomarkers for vascular health or disease progression, enabling earlier detection and monitoring of atherosclerotic burden. Integration of such biomarkers into clinical workflows could refine risk stratification, guiding therapeutic decisions with higher precision.

To conclude, this pioneering perivascular adipose single-cell atlas hallmarks a new era in understanding vascular remodeling mechanisms underpinning atherosclerosis. By spotlighting CD55+ adipose-derived stem cells as crucial players in the dynamic interplay between adipose tissue and vasculature, it paves the way for targeted therapies that may revolutionize cardiovascular disease management. The convergence of single-cell technology, molecular biology, and clinical translational potential in this study epitomizes the future of cardiovascular research, promising to alleviate the global burden of atherosclerotic disease through innovative science-driven solutions.

Subject of Research: The role of perivascular adipose-derived CD55+ stem cells in vascular remodeling during atherosclerosis.

Article Title: Perivascular adipose single-cell atlas identifies CD55+ adipose-derived stem cells as vascular remodeling regulators in atherosclerosis.

Article References:
Chen, J., Li, K., Shao, J. et al. Perivascular adipose single-cell atlas identifies CD55+ adipose-derived stem cells as vascular remodeling regulators in atherosclerosis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72962-z

Image Credits: AI Generated

At the heart of this revelation stands the imidazoline receptor I1R, ubiquitously expressed in immune cells, acting as a specific sensor for ImP. The ability of ImP to engage I1R was scrupulously confirmed through a combination of pharmacological antagonist treatments and genetic silencing techniques in bone marrow-derived macrophages (BMDMs) and mouse embryonic fibroblasts (MEFs). Importantly, antagonists selective for I1R, such as AGN192403, demonstrated a potent blockade of ImP-induced phosphorylation of the ribosomal protein S6 (p-S6), an mTOR pathway hallmark, and the secretion of the key inflammatory cytokine tumor necrosis factor (TNF). These data strategically pinpoint I1R as the critical conduit translating microbial metabolite signals into pro-inflammatory outputs conducive to atherosclerosis.

The mechanistic insights into ImP’s signaling pathway reveal a sophisticated interplay whereby ImP induces mTOR activation and subsequent inflammatory gene expression through its interaction with I1R. Phosphoproteomic dissection highlights that inhibition of I1R effectively quenches downstream mTOR activation, positioning this receptor as a gatekeeper of ImP’s pathophysiological influence. The specificity of this signaling axis was further substantiated by RNA interference targeting the gene encoding I1R (Nisch), which abrogated ImP-mediated inflammatory responses, thereby reinforcing the strict dependency on this receptor pathway.

To dissect the cell-specific contributions of I1R in the pathogenesis of atherosclerosis, investigators engineered myeloid-specific knockout mice (Lyz2ΔNisch) through the deletion of Nisch in myeloid lineage cells. This refined genetic model exhibited selective ablation of I1R in spleen myeloid populations while preserving receptor expression in lymphocytes, thus isolating the myeloid compartment’s role. Functional assays demonstrated that ImP-triggered induction of p-S6 and inflammatory cytokine production was completely dependent on myeloid I1R expression, elegantly confirming the receptor’s authoritative role in myeloid-driven atherogenic inflammation.

The translational relevance of these findings was decisively tested in an atherosclerosis-prone Ldlr knockout mouse model. Bone marrow transplantation from either wildtype Nisch-floxed or myeloid-specific I1R-deficient donors was followed by ImP administration, exposing the phenotypic ramifications of myeloid I1R absence during disease challenge. Remarkably, mice lacking myeloid I1R were impervious to ImP-induced atherosclerotic lesion development, decisively linking myeloid I1R to disease exacerbation and underscoring its therapeutic potential.

Pharmacological blockade of the ImP-I1R interaction yielded equally potent protective effects in atherosclerosis. Administration of the selective I1R antagonist AGN192403 alongside ImP in Apoe-deficient mice forestalled the formation of lipid-rich atherosclerotic plaques without influencing systemic ImP levels or lipid profiles. This underlines that blockade targets receptor-mediated immune activation rather than metabolic availability of the ligand. Additionally, AGN192403 treatment attenuated the expansion of pro-inflammatory Ly6C^hi monocytes and T helper 1 (T_H1) cells in circulation, alongside a dampened systemic cytokine milieu typified by TNF and interferon gamma. These immunomodulatory changes orchestrated by receptor blockade reflect a profound recalibration of the immune landscape underpinning atherogenesis.

Beyond systemic immunity, AGN192403 suppressed the localized arterial immune microenvironment alterations driven by ImP. Notably, the drug normalized the elevated ratio of pro-inflammatory T_H1 cells to regulatory T cells (T_reg) within the aortic infiltrate, mitigating immune cell imbalance that potentiates vascular inflammation. Furthermore, it prevented the recruitment of activated macrophages and B cells to the vessel wall, indicative of a comprehensive immunosuppressive effect shaping atheroprotective tissue homeostasis. These findings meticulously connect receptor pharmacology to cellular immunology within the vascular niche.

Extending the therapeutic implications, AGN192403 was evaluated in a high-cholesterol dietary context, a model closely mirroring human atherosclerosis pathophysiology. In Apoe-deficient mice fed a cholesterol-enriched diet, the addition of AGN192403 effectively curtailed plaque burden and reduced necrotic core formation within aortic lesions, both surrogate markers of disease severity. This outcome not only validates the receptor’s centrality in diet-induced atherogenesis but also proposes I1R antagonism as a promising adjunct to conventional lipid-lowering strategies.

Delving deeper into the molecular underpinnings, the phosphorylation of S6 ribosomal protein emerges as a crucial nexus linking ImP stimulation to the activation of mTOR signaling in macrophages. This event represents an intersection of metabolic sensing and inflammatory programming, enabling ImP to potentiate macrophage activation states conducive to vascular injury. The exquisite sensitivity of this phosphorylation event to I1R inhibition consolidates the receptor’s role as a proximal mediator of metabolic-immune crosstalk.

This compendium of evidence collectively positions the ImP-I1R axis as a critical driver of inflammation and atherosclerosis, illuminating a previously uncharted mechanism by which gut microbiota metabolites orchestrate systemic immune responses with pathological consequences. By demonstrating that I1R deletion or pharmacological antagonism offers robust protection against ImP-induced atherogenesis, the study paves the way for innovative therapeutic strategies targeting microbe-host molecular dialogues.

The broader implications of these findings resonate beyond cardiovascular disease. Given the ubiquity of imidazoline receptors and the systemic circulation of microbial metabolites, it is plausible that similar mechanisms may influence other chronic inflammatory disorders. Targeted blockade of I1R could therefore represent a versatile platform to modulate maladaptive immune activation in a spectrum of diseases driven by microbiome-derived metabolites.

In sum, the identification of imidazole propionate as an endogenous ligand for the imidazoline receptor I1R reframes our understanding of microbiota-host interactions and their impact on vascular inflammation and atherosclerosis. The translational potential encapsulated within this pathway, underscored by effective pharmacological inhibition, propels the ImP-I1R axis into the spotlight as a therapeutic target deserving of intense clinical investigation. Future research will undoubtedly explore the nuances of receptor signaling, ligand diversity, and interventional timing to harness this axis for cardiovascular protection.

Subject of Research:
The investigation delineates imidazole propionate as a microbial metabolite that promotes atherosclerosis via activation of the imidazoline receptor I1R on myeloid cells, identifying this receptor as a therapeutic target.

Article Title:
Imidazole propionate is a driver and therapeutic target in atherosclerosis.

Article References:
Mastrangelo, A., Robles-Vera, I., Mañanes, D. et al. Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature (2025). https://doi.org/10.1038/s41586-025-09263-w

Image Credits:
AI Generated